NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Sector Expert: Sean Lavin

BTIG Research



Recent Quotes

"We see about 20% upside in ISRG over the next year."

— Sean Lavin, Lazard Capital Markets (1/14/13)
more >

"We expect ISRG's margins and earnings to expand long term."

— Sean Lavin, Lazard Capital Markets (12/20/12)
more >

"MDT is the most diversified medical device company in the world."

— Sean Lavin, Lazard Capital Markets (10/31/12)
more >

"Our rating of EW is Buy."

— Sean Lavin, Lazard Capital Markets (8/10/12)
more >

"We rate EW shares a Buy."

— Sean Lavin, Lazard Capital Markets (7/9/12)
more >

"ISRG's funnel in the U.S. remains immense."

— Sean Lavin, BTIG Research (5/25/12)
more >

"EW's Sapien 3 FIM data looks quite promising; our rating is Buy."

— Sean Lavin, Lazard Capital Markets (5/24/12)
more >

"MDT is the world's most diversified pure play medical device company."

— Sean Lavin, Lazard Capital Markets (4/30/12)
more >



Due to permission requirements, not all quotes are shown.